Investment Date: March 2024

Sector: Pharmaceuticals

Country: Europe

ADALVO

Established in 2018, Adalvo stands as a global B2B generics pharmaceutical company with commercial partnerships in more than 130 countries and over 140 commercial partners globally. Adalvo focuses on developing and commercialising generic pharmaceuticals across a wide range of therapeutic areas and technologies in partnership with manufacturing partners and large pharmaceutical companies. With headquarters in Malta, the company has teams present in over 15 countries including Switzerland, the UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic, and India.